Check-Cap Ltd. (CHEK) Sets New 1-Year Low on Disappointing Earnings

Check-Cap Ltd. (NASDAQ:CHEK) hit a new 52-week low on Friday following a dissappointing earnings announcement. The stock traded as low as $1.71 and last traded at $1.71, with a volume of 22,832 shares traded. The stock had previously closed at $1.75.

The medical research company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.16) by $0.01.

Several brokerages have recently commented on CHEK. Zacks Investment Research lowered Check-Cap from a “buy” rating to a “hold” rating in a report on Tuesday, May 23rd. Maxim Group reiterated a “buy” rating on shares of Check-Cap in a report on Tuesday, May 30th. Finally, ValuEngine upgraded Check-Cap from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $5.00.

An institutional investor recently raised its position in Check-Cap stock. Knott David M raised its stake in shares of Check-Cap Ltd. (NASDAQ:CHEK) by 1.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 162,871 shares of the medical research company’s stock after buying an additional 3,000 shares during the period. Knott David M owned approximately 1.05% of Check-Cap worth $349,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 13.35% of the company’s stock.

The company’s 50 day moving average is $1.85 and its 200 day moving average is $2.06. The firm’s market capitalization is $26.10 million.

ILLEGAL ACTIVITY NOTICE: “Check-Cap Ltd. (CHEK) Sets New 1-Year Low on Disappointing Earnings” was first posted by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at

Check-Cap Company Profile

Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC)-based work station for data reconstruction and image processing.

What are top analysts saying about Check-Cap Ltd.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Check-Cap Ltd. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit